Ixazomib/lenalidomide/dexamethasone Moreau P, Pylypenko H, Grosicki S, et al. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. Intergroupe Français du Myélome. Harousseau JL, Mathiot C, Attal M, et al. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. If you can see this message there appears to be an issue with the javascript in your browser. [Guideline] National Comprehensive Cancer Network. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract 450]. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. If you are still having an issue, please Please note that the guidelines listed are Acrobat PDF files.Please maximize your browser window to view these guidelines. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, et al. Bisphosphonates should be administered IV every 3 to 4 weeks during initial therapy, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. Petrucci MT, Giraldo P, Corradini P, et al. The combination of cyclophosphamide, thalidomide, and dexamethasone is also recommended for the primary treatment of amyloidosis.The NCCN, American Society of Clinical Oncology (ASCO), and International Myeloma Workshop clinical guidelines for prevention of venous thromboembolism agree that patients with multiple myeloma who are receiving thalidomide- or lenalidomide-based regimens with chemotherapy and/or dexamethasone should receive prophylactic anticoagulation therapy with either aspirin or low molecular weight heparin (LMWH) for lower-risk patients and LMWH for higher-risk patients.A joint American Society of Hematology (ASH) and ASCO clinical practice guideline on the use of erythropoiesis-stimulating agents (ESAs) in cancer was updated in 2010. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. We would like to show you a description here but the site won’t allow us. Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate. Blood transfusion is also a therapeutic option Myeloma Aredia Study Group. Lokhorst HM, van der Holt B, Zweegman S, et al. [Guideline] National Comprehensive Cancer Network. [Guideline] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al.

Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus is recommended as the novel standard for the detection of lytic lesions in myeloma. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Complete blood count (CBC), differential, platelet count

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. A single autologous stem cell transplant is the preferred approach in transplant-eligible patients

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Serum LDH and beta-2 microglobulin As endorsed by The Leukemia & Lymphoma Society and the Multiple Myeloma Research Foundation, the NCCN Guidelines For Patients, as produced by the National Comprehensive Cancer Network (NCCN), explains testing and treatments for multiple myeloma, as well as provides information to help patients with multiple myeloma make informed treatment … NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesThe NCCN Guidelines are copyrighted by the NCCN.